We have also shown that PR1-CTL are not detectable in newly diagnosed CML patients or in patients that do not respond to treatment with IFN and that PR1-CTL contribute to T cell mediated anti-CML immunity [16]. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.